nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.09.2003 | Original Paper

Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients

verfasst von: Alfonso Ferrara, Marion Nonn, Peter Sehr, Carola Schreckenberger, Michael Pawlita, Matthias Dürst, Achim Schneider, Andreas M. Kaufmann

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 9/2003

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Human papillomavirus (HPV) type 16 and 18 are the most prevalent genotypes in cervical cancer. The viral oncoproteins E6 and E7 are considered to be tumor-specific targets for immunotherapy. HPV E7 antigen-loaded autologous dendritic cells (DC) were evaluated as cellular tumor vaccine in a case series of cervical cancer patients.

Methods

Autologous monocyte-derived DCs were pulsed with recombinant HPV16 E7 or HPV18 E7 oncoprotein and administered to 15 stage IV cervical cancer patients. Safety, toxicity, and induction of serological and cellular immune responses were monitored.

Results

The vaccine was well-tolerated and no local or systemic side effects or toxicity were recorded. A specific serologic response was seen in 3/11 evaluated patients. Specific cellular immune responses (4/11) were detected with 2/10 positive de novo reactions plus one boosted preexistent response in proliferation assays and 3/11 in IFN-γ ELISpot assays. A transient drop in tumor marker SCC was observed in 5/9 evaluable patients but did not correlate with markers of the immune response. No objective clinical response was observed. Tumor biopsies available from four patients showed severe or complete loss of HLA expression in three of the advanced tumors.

Conclusion

Autologous dendritic cells pulsed with HPV E7 protein can induce T cell responses in a portion of late stage cervical cancer patients. Boosting of immune responses by adjuvants and vaccination of tumor HLA-positive patients will be mandatory in future trials.

Adams M, Borysiewicz LK, Fiander A, Man S, Jasani B, Navabi H, Lipetz C, Evans AS, Mason M (2001) Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 19:2549–2556CrossRefPubMed

Borysiewicz LK, Fiander A, Nimako M, Man S, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell MEG, Rutherford E, Hickling JK, Inglis SC (1996) A recombinant vaccinia virus encoding human papilloma virus types 16 and 18 E6 and E7 proteins as immuotherapy for cervical cancer. Lancet 347:1523–1527PubMed

Cromme FV, van Bommel PF, Walboomers JM, Gallee MP, Stern PL, Kenemans P, Helmerhorst TJ, Stukart MJ, Meijer C J (1994) Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer 69:1176–1187PubMed

Delgado G, Bundy B, Zaino R, Sevin B, Creasman WT, Major F (1990) Prospective surgical-pathological study of disease free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynaecologic Oncology Group Study. Gynec Oncol 38:352–357

Helmerhorst TJ, Meijer CJ (2002) Cervical cancer should be considered as a rare complication of oncogenic HPV infection rather than a STD. Int J Gynecol Cancer 12:235–236CrossRefPubMed

Hernando JJ, Park TW, Kübler K, Offergeld R, Schlebusch H, Bauknecht T (2002) Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 51:45–52CrossRefPubMed

Honma S, Tsukada S, Honda S, Nakamura M, Takakuwa K, Maruhashi T, Kodama S, Kanazawa T, Takahashi T, Tanaka K (1994) Biological-clinical significance of selective loss of HLA-class-I allelic product expression in squamous-cell carcinoma of the uterine cervix. Int J Cancer 57:650–655PubMed

Hopfl R, Heim K, Christensen N, Zumbach K, Wieland U, Volgger B, Widschwendter A, Haimbuchner S, Muller-Holzner E, Pawlita M, Pfister H, Fritsch P (2000) Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet 356:1985–1986CrossRefPubMed

Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM (1997) A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 35:791–795PubMed

Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27:3135–3142PubMed

Kaufmann AM, Gissmann L, Schreckenberger C, Qiao L (1997) Cervical carcinoma cells transfected with the CD80 gene elicit a primary cytotoxic T lymphocyte response specific for HPV 16 E7 antigens. Cancer Gene Ther 4:377–382PubMed

Kaufmann AM, Nieland J, Schinz M, Nonn M, Gabelsberger J, Meissner H, Muller RT, Jochmus I, Gissmann L, Schneider A, Durst M (2001) HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int J Cancer 92:285–293CrossRefPubMed

Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K, Hickling J, Boswell CM, Stacey SN, Kitchener HC, Gillard J, Wanders J, Roberts JStC, Zwierzina H (2002) Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified HPV16 and 18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res (in press)

Kono K, Ressing ME, Brandt RM, Melief CJ, Potkul RK, Andersson B, Petersson M, Kast WM, Kiessling R (1996) Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 2:1825–1828PubMed

Liu Y, Chiriva-Internati M, Grizzi F, Salati E, Roman JJ, Lim S, Hermonat PL (2001) Rapid induction of cytotoxic T cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector. Cancer Gene Ther 8:948–957CrossRefPubMed

Meier W, Stieber P, Hasholzner U, Baumgartner L, Fateh-Moghadam A (1997) Prognostic significance of squamous cell carcinoma (SCC) antigen in primary advanced and recurrent cervical carcinoma. Anticancer Res 17:2959–2962PubMed

Micke O, Prott FJ, Schafer U, Tangerding S, Potter R, Willich N (2000) The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res 20:5113–5115PubMed

Munderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast MW, Fascio G, Marty V, Weber J (2000) A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6:3406–3416

Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R (1989) The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63:4417–4424

Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4:328–332PubMed

Nonn M, Schinz M, Zumbach K, Pawlita P, Schneider A, Dürst M, Kaufmann AM (2003) Dendritic cell-based tumor vaccine for cervical cancer I: in vitro vaccination with recombinant protein pulsed dendritic cells induces specific T cells to HPV16 E7 and HPV18 E7. J Cancer Res Clin Oncol 129:DOI 10.1007/s00432-003-0462-6

Pectasides D, Economides N, Bourazanis J, Podzazizou P, Gogou L, Koutsiouba P, Athanassiou A (1994) Squamous cell carcinoma antigen, tumor-associated trypsin inhibitor, and carcinoembryonic antigen for monitoring cervical cancer. Am J Clin Oncol 17:307–312PubMed

Pisani P, Parkin DM, Ferlay J (1995) Estimates of the world wide mortality from major cancers in 1985. Implications for prevention and projection of future burden. Int J Cancer 55:891–903

Ressing ME, Sette A, Brandt RMP, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJM, Kast WM (1995) Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 154:5934–594PubMed

Ressing ME, van Driel WJ, Brandt RM, Kenter GG, de Jong JH, Bauknecht T, Fleuren GJ, Hoogerhout P, Offringa R, Sette A, Celis E, Grey H, Trimbos BJ, Kast WM, Melief CJ (2000) Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 23:255–266CrossRefPubMed

Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, Seliger B (2001) Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 19:1211–1220PubMed

Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Niederwieser D, Schuler G (1996) Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 196:137–151PubMed

Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan D, Pecorelli S, Parham GP, Cannon MJ (1999) Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol 73:5402–5410PubMed

Santin AD, Bellone S, Gokden M, Cannon MJ, Parham GP (2002) Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med 346:1752–1753CrossRefPubMed

Schoell WMJ, Mirhashemi R, Liu B, Janicek MF, Podack ER, Penalver MA, Averette HE (1999) Generation of tumor-specific cytotoxic T lymphocytes by stimulation with HPV type 16 E7 peptide-pulsed dendritic cells: an approach to immunotherapy of cervical cancer. Gynec Oncol 74:448–455CrossRef

Schorge JO, Molpus KL, Koelliker D, Nikui N, Goodman A, Fuller AF (1997) Stage IB and IIA cervical cancer with negative lymph nodes: the role of adjuvant radiotherapy after radical hysterectomy. Gynec Oncol 66:31–35CrossRef

Schuler G, Steinman RM (1997) Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 186:1183–1187PubMed

Sehr P, Zumbach K, Pawlita M (2001) A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods 253:153–162CrossRefPubMed

Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271–296PubMed

von Knebel Doeberitz M, Oltersdorf T, Schwarz E, Gissmann L (1988) Correlation of modified human papilloma virus early gene expression with altered growth properties in C4–1 cervical carcinoma cells. Cancer Res 48:3780–3786PubMed

von Knebel Doeberitz M, Rittmuller C, zur Hausen H, Durst M (1992) Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int J Cancer 51:831–834PubMed

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 89:12–19CrossRef

Wollscheid V, Kuhne-Heid R, Stein I, Jansen L, Kollner S, Schneider A, Durst M (2002) Identification of a new proliferation-associated protein NET-1/C4.8 characteristic for a subset of high-grade cervical intraepithelial neoplasia and cervical carcinomas. Int J Cancer 99:771–775CrossRefPubMed

Zur Hausen H (1999) Papillomaviruses in human cancers. Proc Assoc Am Physicians 111:581–581PubMed

Titel: Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients
verfasst von: Alfonso Ferrara
Marion Nonn
Peter Sehr
Carola Schreckenberger
Michael Pawlita
Matthias Dürst
Achim Schneider
Andreas M. Kaufmann
Publikationsdatum: 01.09.2003
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 9/2003
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-003-0463-5

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2003

Quantitative reverse transcriptase polymerase chain reaction analysis for KiSS-1 and orphan G-protein-coupled receptor (hOT7T175) gene expression in hepatocellular carcinoma

Expression of caveolin-1 in gastrointestinal and extraintestinal cancers

p34cdc2 expression is an independent indicator for lymph node metastasis in colorectal carcinoma

Induction of apoptosis in mouse liver adenoma and carcinoma in vivo by transforming growth factor-β1

Surgery for large primary liver cancer more than 10 cm in diameter

Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie